Concor Combi

Quick links to important sections

Concor Combi

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Concor Combi

Concor Combi is a Fixed-Dose Combination (FDC) medicine classified as an antihypertensive agent used for the management of high blood pressure, or essential hypertension. This synthetic preparation combines two distinct pharmacological classes into one single unit, reflecting an advanced therapeutic strategy for continuous blood pressure control.

Property Description
Active ingredient Bisoprolol and Amlodipine
Form Oral Tablet (Single-Pill-Combination)
Pharmacological class Beta-Blocker and Calcium Channel Blocker
Common use Managing High Blood Pressure
Origin Synthetic

What Type of Medicine is Concor Combi?

Concor Combi is an antihypertensive agent that combines a Beta-Blocker and a Calcium Channel Blocker into a single drug entity. This formulation is known as a Single-Pill-Combination (SPC) and is designed to simplify the treatment regimen for patients who require both classes of medication, helping to ensure consistent dosing. The use of fixed-dose combinations is clinically recognized for aiding the long-term management of chronic conditions, a strategy supported by clinical evidence for improving therapeutic outcomes.


What is Concor Combi Made Of and What Form is It?

The medicine contains two active ingredients with established roles in cardiovascular therapy: Bisoprolol and Amlodipine. The typical forms used are Bisoprolol fumarate and Amlodipine besilate. The dosage form is an oral tablet for the oral route of administration. The purpose of the Fixed-Dose Combination is to deliver both agents in a precise ratio within every pill, simplifying the daily regimen compared to taking two separate tablets.


How Does the Combination Help Manage Blood Pressure?

The combination provides robust blood pressure control by merging a Heart Calming Action with a Vessel Widening Action. Bisoprolol reduces the speed and force of the heart's pumping, minimizing strain on the heart muscle. In parallel, Amlodipine relaxes and expands the blood vessels, easing the flow of blood through the arteries. This synergistic and complementary approach is often utilized when a patient's hypertension is not adequately controlled by either of the individual components alone.

What side effects are possible with Concor Combi?

Possible Side Effects and Safety Information

The safety profile for the Bisoprolol/Amlodipine Fixed-Dose Combination is derived from the known adverse reactions of its two components, categorized by frequency and the physiological system affected, following regulatory standards.

Frequency-Classified Adverse Reactions

The official labeling classifies potential effects into categories based on incidence:

  • Very Common: Peripheral edema (swelling), a common reaction associated with the amlodipine component.
  • Common: Adverse reactions frequently documented include headache, dizziness, fatigue, somnolence, bradycardia (slow heart rate), cold or numb extremities, nausea, abdominal pain, and diarrhea or constipation.
  • Uncommon / Rare: Less frequently observed effects include hypotension, palpitations, flushing, erectile dysfunction, muscle cramps, hypersensitivity reactions (such as rash), and certain changes in liver enzymes.

System-Organ Classes and Serious Adverse Reactions

Adverse effects are formally grouped into System-Organ Classes (SOCs) such as Nervous system disorders, Cardiac disorders, Vascular disorders, and Gastrointestinal disorders.

Regulatory documents also detail conditions that constitute Serious Adverse Reactions or contraindications, defining high-level safety constraints. These include acute heart failure or decompensation, cardiogenic shock, severe hypotension, and certain atrioventricular (AV) heart blocks (second or third degree without a pacemaker).

Population-Specific Safety Considerations

The label defines specific safety considerations for patient populations where the risk profile may differ. For patients with severe renal or hepatic impairment, the dose of the bisoprolol component must be restricted. The product is not recommended for use in children and adolescents (under 18 years) as safety and efficacy have not been formally established. Abrupt cessation of this medicine must be strictly avoided, especially in individuals with ischemic heart disease, as this is associated with a risk of transitory clinical worsening.

Overdose and Emergency Response

An overdose of Concor Combi involves the acute physiological effects of both a beta-blocker (bisoprolol) and a calcium channel blocker (amlodipine). Official regulatory information documents that overexposure may lead to potentially severe and life-threatening manifestations affecting multiple physiological systems.

Documented Clinical Manifestations

The most critical presentations are linked to the cardiovascular system. These include profound and prolonged hypotension (low blood pressure), severe bradycardia (slowed heart rate), and atrioventricular (AV) block, which may rapidly lead to cardiovascular collapse or shock. Other serious effects documented in regulatory sources include acute heart failure and respiratory compromise such as bronchospasm. Systemic effects involve the central nervous system, presenting as dizziness, confusion, convulsions (seizures), or coma. Hypoglycemia (low blood sugar) is also noted, particularly as a consideration in children experiencing overdose.

Required Emergency Action

Regulatory guidance strictly mandates that a person must seek immediate medical attention for a suspected overdose. Urgent contact with emergency services is required immediately if the individual has collapsed, is experiencing trouble breathing, or exhibits a seizure. Management is officially designated as symptomatic and supportive treatment, as no specific antidote is known for this combination. Continuous cardiac monitoring and procedural options like activated charcoal are required components of the official management protocol.

Therapeutic Uses of Concor Combi

Concor Combi is primarily used for the long-term management of essential hypertension (high blood pressure) when treatment with a single blood pressure medication is insufficient or has failed to achieve the target goal. This combination contributes to stable management over pathologically elevated systolic and diastolic blood pressure values. The medication is applied in addressing two key issues: the elevated pressure itself, and the symptom of an inappropriately elevated heart rate that contributes to overall circulatory strain. It is considered relevant for adults with chronic conditions such as Coronary Artery Disease (CAD), and it may be part of symptomatic management as substitution therapy to simplify complex routines.

“The Single-Pill-Combination format may assist with patient adherence by simplifying the daily dosing routine.”

This formulation is commonly used to help with patients who require the combination of Bisoprolol and Amlodipine to manage their condition effectively. The dual action helps reduce the heart's workload, and **assists with maintaining functional stability.

Quick Fact: Support for Symptoms Linked to Circulatory Strain
This combination may help ease symptom load and contributes to consistent blood pressure management over the long term, supporting the patient with a simplified management strategy.

Regulatory References

  1. ClinicalTrials.gov entry for the combination drug

Eligibility and Restrictions for Use

Who Can and Cannot Use Concor Combi? — Official Regulatory Information

The eligibility for Concor Combi (Bisoprolol/Amlodipine) is strictly defined by government regulatory documents, outlining populations that must not use the medicine and groups that require special caution.


Contraindications (Must Not Use)

Use of Concor Combi is prohibited for individuals with known hypersensitivity to its components or dihydropyridine derivatives, and for those with severe, unmanaged cardiovascular or respiratory conditions. This includes:

  • Acute heart failure or decompensation requiring intravenous therapy.
  • Cardiogenic shock, severe hypotension, or second/third-degree AV block (without a pacemaker).
  • Severe bronchial asthma or severe Chronic Obstructive Pulmonary Disease (COPD).
  • Untreated phaeochromocytoma or metabolic acidosis.

Restricted and Special-Caution Populations

  • Age: The medicine cannot be recommended for children and adolescents below 18 years of age due to a lack of established safety and efficacy data. Older adults may use the standard dose, but caution is advised when increasing the dosage.
  • Organ Impairment: Patients with severe renal impairment (creatinine clearance <20 mL/min) or severe hepatic impairment must be monitored closely and the bisoprolol component should not exceed 10 mg daily. The drug should also be administered with special caution in all patients with liver impairment.
  • Life Stage: Use is not recommended during pregnancy or breastfeeding.

What should I know about interactions with other medicines?

The official interaction profile for this fixed-dose combination is defined by pharmacodynamic effects from the Bisoprolol component and pharmacokinetic modulation involving Amlodipine. Co-administration with Non-Dihydropyridine Calcium Channel Blockers like Verapamil or Diltiazem-type agents is officially classified as not recommended due to the potential for severe additive reduction in heart rate and cardiac conduction. Similarly, centrally-acting antihypertensive drugs such as Clonidine are not recommended because of the risk of significant cardiovascular depression and rebound hypertension upon withdrawal.

The Amlodipine component is subject to pharmacokinetic interactions mediated by the CYP3A4 enzyme system. Strong or moderate CYP3A4 inhibitors, including Ketoconazole, may cause a documented increase in Amlodipine plasma concentration. Conversely, strong CYP3A4 inducers like Rifampicin or the herbal product St. John's Wort may lead to lower plasma concentrations. Amlodipine also impacts the exposure of other drugs, resulting in an officially documented increase in Simvastatin levels and a risk of elevated blood levels of Tacrolimus and Cyclosporine.

Regarding consumption restrictions, administration with Grapefruit or Grapefruit Juice is not recommended due to the possibility of increased Amlodipine bioavailability. Patients with impaired hepatic function require special caution, as the prolonged elimination half-life of Amlodipine may heighten the significance of these pharmacokinetic interactions.

Mechanism of Action

Blocking the Cardiac Adrenergic System

Bisoprolol acts as a selective antagonist of the beta1-adrenergic receptor in the heart. This competitively inhibits activation by circulating catecholamines, dampening the sympathetic signal cascade. The direct intervention leads to a reduction in both heart rate and the force of contraction, lowering the cardiac output and reducing the mechanical load on the cardiac tissue. This mechanism also suppresses renin release from the kidney's juxtaglomerular cells.

Inhibiting Vascular Smooth Muscle Contraction

Amlodipine functions as an inhibitor of the L-type voltage-gated calcium channels on vascular smooth muscle. Preventing the necessary influx of calcium ions (Ca^2+) stops the contraction process, causing the arteries to widen (vasodilation). This effect reduces the Total Peripheral Resistance (TPR), which is the systemic opposition to blood flow.

Synergistic Hemodynamic Control

The two mechanisms are complementary. Bisoprolol's action prevents the reflex tachycardia that can be triggered by Amlodipine's vessel-widening effect. This combined approach ensures simultaneous modulation of the heart's pumping action and the resistance of the blood vessels, contributing to the overall modulation of systemic pressure.

Dosage and Administration Information

Official Administration Guidelines for Concor Combi

Concor Combi (Bisoprolol/Amlodipine) is a fixed-dose combination (FDC) therapy administered as an oral tablet. The usage protocol is defined by specific guidelines covering dosing, frequency, administration constraints, and adjustments for certain patient populations.

Dosing and Frequency

The standard regimen is one tablet once daily. The medicine is primarily approved for use as substitution therapy in patients whose blood pressure is already controlled on the individual components given separately at the same dose level.

The available fixed-dose strengths, which constitute the maximum daily dose for the FDC, include: 5 mg/5 mg, 5 mg/10 mg, 10 mg/5 mg, and 10 mg/10 mg (Bisoprolol/Amlodipine).

Administration Instructions

The tablet must be taken in the morning. It can be consumed with or without food. Patients must swallow the tablet whole with some liquid and must not chew or crush it. If a tablet has a score line, it is intended to facilitate ease of swallowing and does not indicate the tablet may be divided into equal doses.

If a dose is missed, it should be taken as soon as the patient remembers, unless it is close to the time for the next scheduled dose, in which case the missed dose should be skipped; a double dose should not be taken.

Population-Specific Constraints

Administration rules require caution and dose limits for specific groups: in patients with severe renal impairment (creatinine clearance <20 mL/min) or severe hepatic impairment, the dose of the Bisoprolol component must not exceed 10 mg daily. Use in the pediatric population (below 18 years of age) is not recommended due to a lack of established safety and efficacy data.

Treatment must not be abruptly discontinued; a gradual dose reduction is the required procedural step for cessation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Concor Combi

Evidence for Essential Hypertension

Research has primarily examined the single-pill combination in adults whose high blood pressure (essential hypertension) was not controlled by treatment with a single drug alone. Randomized Controlled Trials (RCTs) were used in research examining how the combination measured against monotherapy. Researchers monitored the main outcomes of interest: changes in Systolic and Diastolic Blood Pressure (BP). These trials monitored BP measurements over short periods, typically up to 18 weeks, and reported observed changes, with findings contributing to the broader evidence landscape. However, these trials typically monitored blood pressure as a physiological marker, rather than focusing on definitive long-term clinical outcomes.

Research on Simplified Switching

Studies have explored the use of the combination in substitution therapy, where patients stable on separate Bisoprolol and Amlodipine tablets were switched to the single-pill combination. These studies were often large-scale observational cohorts applied in studies examining patient-reported experiences related to managing their medication routine. Data from these studies described patterns in patient adherence when subjects transitioned to the single tablet. Research describes the nature of these studies as observational, meaning they can describe patterns observed in the studies (an association), but cannot definitively establish a causal link to any changes in adherence.

Evidence Gaps and Limitations

Follow-up durations were limited in many of the core efficacy trials. Consequently, long-term effects are not fully established with the highest level of evidence, and there is limited information for long-term outcomes specific to the FDC itself over years of continuous use. A significant gap is the lack of extensive, dedicated RCTs focusing on long-term, definitive cardiovascular event rates. The initial regulatory review examined data comparing the combination to the known evidence of the two components taken individually. Data for certain groups remain insufficient, particularly for complex patient subgroups or populations outside of adults.

Key Studies & References Hypertension in adults: diagnosis and management (NICE Guideline NG136) - Recommendations

Frequently Asked Questions (FAQ)

Common questions about Concor Combi (FAQ)


Q: What is the main reason a doctor would prescribe Concor Combi?

The official product information states that Concor Combi is indicated for treating essential hypertension (high blood pressure). It is typically approved for use as a substitution therapy in patients whose blood pressure is assessed as being controlled on the individual components (Bisoprolol and Amlodipine) taken separately at the same doses.


Q: Is Concor Combi used only for high blood pressure?

The official indication for this fixed-dose combination medicine is strictly the treatment of hypertension (high blood pressure). The regulatory label for Concor Combi defines the indication as this condition.


Q: Does Concor Combi treat other heart conditions besides hypertension?

According to official regulatory documents, the sole condition listed for the use of Concor Combi is hypertension. If there are other heart conditions, the treating physician determines the appropriateness of the medication.


Q: Does Concor Combi need to be taken long-term?

As hypertension is a chronic condition, treatment with this medicine is generally intended for long-term management. Regulatory warnings indicate that the medication should not be stopped abruptly, and a gradual dose reduction is required for cessation.


Q: Is weight gain a possible side effect of Concor Combi?

Weight changes are listed in official product information as a possible metabolic side effect. Additionally, sudden, unexplained weight gain or swelling can be a sign of a more serious condition, such as fluid retention or heart failure, and this is a sign that should be addressed by a healthcare provider.


Q: Does Concor Combi affect blood sugar levels?

Regulatory documents note that the Bisoprolol component of this medicine may affect blood sugar levels. Furthermore, it can mask the usual physical signs of low blood sugar (hypoglycaemia), such as an increased pulse rate, which is a reason for caution if the patient has diabetes.


Q: Can Concor Combi be taken with common pain relievers like ibuprofen?

Official interaction profiles indicate that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may interact with this medicine. This interaction may reduce the effectiveness of the Bisoprolol component, which may result in an increase in blood pressure.


Q: Does alcohol interact with Concor Combi?

Yes, the official information advises caution regarding alcohol consumption. Drinking alcohol can increase the risk of side effects such as dizziness, light-headedness, or fainting spells.


Q: What foods or supplements should be avoided while using Concor Combi?

Official product information suggests that consuming Grapefruit or Grapefruit Juice is generally cautioned against due to a potential interaction. Furthermore, limited specific safety information is available for co-administering this drug with most other herbal remedies and supplements.


Q: Can I take cough or cold medicine while on Concor Combi?

Official cautions exist regarding the use of certain cold and cough medicines while taking Concor Combi. Specifically, those containing active ingredients like pseudoephedrine or xylometazoline may be associated with an interaction with this medicine.


Q: Can Concor Combi be used by people with asthma or COPD?

The official product information states that Concor Combi is contraindicated in cases of severe bronchial asthma. For people with other chronic obstructive lung diseases (COPD), it must be used with special caution, and may necessitate review of concomitant bronchodilator therapy by the prescribing physician.


Q: Is Concor Combi suitable for older patients?

According to the regulatory information, usual doses can be administered to older patients. However, official guidelines advise special caution when the dosage is being increased.


Q: Is it common to have vivid dreams or insomnia on Concor Combi?

The official side effect profile lists insomnia (sleeplessness) as a common adverse reaction. Nightmares are also noted in regulatory documents but are classified as a rare side effect.


Q: Can Concor Combi be used during pregnancy or while breastfeeding?

Official regulatory documents state that use during pregnancy and lactation is generally not recommended. Regulatory guidelines specify that use during these times is limited to situations where the expected benefit is considered to outweigh potential risks.


Q: Does Concor Combi affect the ability to drive or operate machinery?

The official product information includes warnings that this medicine may affect your coordination, reaction time, or judgment. Official warnings state that patients should not drive or operate machinery until they are aware of how the medication affects them.


Q: Does Concor Combi contain lactose or gluten?

The tablets usually contain lactose (as monohydrate) as an inactive ingredient. Regulatory documents do not typically contain specific warnings about gluten unless a wheat-derived excipient is used in the formulation.


Q: Does Concor Combi help protect against stroke or heart attack?

Official studies indicate that antihypertensive therapy, which includes the components of this medicine, has been shown to reduce the risk of major cardiovascular events. This includes conditions like stroke and heart attack in patients being treated for high blood pressure.


Q: Can Concor Combi cause dry mouth?

Yes, the official side effect profile lists dry mouth as a common adverse reaction that can occur with the use of this medication.


Q: Is it normal to feel a tingling sensation when taking Concor Combi?

The official side effect listing includes abnormal or decreased touch sensation as a less common effect. A healthcare provider can assess whether any tingling sensation is related to this described effect.


Q: How does Concor Combi compare to similar medicines in official studies?

Official research primarily examines the fixed-dose combination as a substitution therapy for patients already stable on the individual components. The two component medicines are frequently studied in clinical trials and compared to other drug classes to inform treatment guidelines.


Q: Does Concor Combi have a risk of causing depression?

Official regulatory documents list depression as an uncommon side effect that may be associated with this medicine.


Q: Do I need to check my pulse regularly while taking Concor Combi?

Because this medicine reduces your heart rate and can mask signs of low blood sugar (like a fast pulse), the prescribing physician is expected to check your progress at regular visits. This is to monitor for unwanted effects, including a very slow heart rate.


Q: Is Concor Combi commonly prescribed for people with diabetes?

Regulatory information states that this medicine must be used with special caution in patients with diabetes. This is because the Bisoprolol component can mask the warning signs of low blood sugar, which is why special caution is exercised when prescribing to patients with diabetes.


Q: Are there any known long-term safety concerns with Concor Combi?

The official documents confirm the treatment is generally intended for long-term management of chronic hypertension. Key long-term safety considerations include the fact that the medicine must not be stopped abruptly and the need for caution in patients with existing heart conditions.

How should Concor Combi be stored and disposed of?

How to Store and Dispose of Concor Combi?

The storage and disposal of this antihypertensive agent must strictly adhere to the conditions documented in official regulatory labeling.

Storage Requirements

Concor Combi tablets must be stored at room temperature, specifically below 30 C (86 F). The product must be kept in its original container and protected from both light and moisture to ensure the stability of the active ingredients, Bisoprolol and Amlodipine. It is mandatory to keep all medicine out of the sight and reach of children to prevent accidental ingestion. The product must not be allowed to freeze.

Disposal Instructions

Expired or unused Concor Combi must not be discarded in household trash or flushed down the toilet (wastewater), as this poses an environmental risk. Disposal must be completed according to local regulations, typically by returning the medicine to a pharmacist or an approved medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Concor Combi found in:

A-Z Index: